GTX (GTXI) Hits New 12-Month Low at $1.30
GTx, Inc. (NASDAQ:GTXI) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $1.30 and last traded at $1.33, with a volume of 5922 shares. The stock had previously closed at $1.35.
Several research firms recently issued reports on GTXI. BidaskClub raised shares of GTX from a “sell” rating to a “hold” rating in a research report on Friday, August 17th. Zacks Investment Research cut shares of GTX from a “buy” rating to a “hold” rating in a research report on Wednesday, November 21st. ValuEngine cut shares of GTX from a “buy” rating to a “hold” rating in a research report on Saturday, September 22nd. Stifel Nicolaus cut shares of GTX from a “buy” rating to a “hold” rating in a research report on Friday, September 21st. Finally, Robert W. Baird cut shares of GTX from an “outperform” rating to a “neutral” rating and set a $17.00 target price on the stock. in a research report on Friday, September 21st. Five investment analysts have rated the stock with a hold rating, The stock currently has a consensus rating of “Hold” and a consensus price target of $21.25.
The stock has a market cap of $32.47 million, a price-to-earnings ratio of -0.75 and a beta of 1.60.
A number of hedge funds have recently made changes to their positions in GTXI. Bridgeway Capital Management Inc. acquired a new position in GTX during the third quarter valued at approximately $431,000. Candriam Luxembourg S.C.A. acquired a new position in GTX during the third quarter valued at approximately $410,000. BlackRock Inc. lifted its position in GTX by 129.5% during the second quarter. BlackRock Inc. now owns 390,150 shares of the biopharmaceutical company’s stock valued at $5,973,000 after buying an additional 220,114 shares in the last quarter. Vivo Capital LLC acquired a new position in GTX during the third quarter valued at approximately $165,000. Finally, Vanguard Group Inc. lifted its position in GTX by 19.3% during the third quarter. Vanguard Group Inc. now owns 467,463 shares of the biopharmaceutical company’s stock valued at $734,000 after buying an additional 75,539 shares in the last quarter. 12.34% of the stock is currently owned by hedge funds and other institutional investors.
GTX Company Profile (NASDAQ:GTXI)
GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.
Recommended Story: Technical Analysis of Stocks, How Can It Help
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.